Rebecca Robertson Named Board Chair at Tandem Diabetes

Tandem Diabetes Care Inc. has chosen Rebecca Robertson to chair of its Board of Directors, succeeding Kim Blickenstaff, who will continue as a board member. Robertson joined Tandem’s board as an independent director in January 2019. 
 
“We’re deeply grateful to Kim for his instrumental contributions to Tandem since 2007, serving first as our CEO then as chair for the past four years,” President/CEO John Sheridan said. “His strategic vision and mission-driven focus has helped to build and shape Tandem from a venture-backed start-up to a worldwide leader in diabetes care.”

Robertson has a track record of helping medical device companies scale in her roles as an engineer, entrepreneur, corporate executive, and board member. She is a founder and general partner at Versant Ventures, where she has specialized in investing in the areas of medical devices and diagnostics since 1999. In addition, through Longridge Business Advisors, she has provided business advisory services and board services since April 2017. Prior to Versant, she served as senior vice president at Chiron Diagnostics, a division of Chiron Corporation, where she had responsibility for the critical care business unit in addition to leading the division’s business development efforts. Prior to joining Chiron, Robertson was a co-founder and vice president at Egis, a consumer products company, and held senior management positions in operations and finance at Lifescan, a Johnson & Johnson Company. 

Robertson earned a bachelor of science degree in chemical engineering from Cornell University.
 
“Beckie has added tremendous value to our board, bringing patient-centric vision and experience with a range of technologies and business models,” Blickenstaff said. “She was a natural choice for this position at an exciting juncture in our evolution, and I am confident that with her leadership, we will continue expanding our global reach and delivering positively different innovation for the diabetes community.”
 
“I am honored to be named chair and am committed to maximizing the opportunities we have at Tandem,” Robertson stated. “Tandem continues to deliver life-changing solutions to people around the world and has a pipeline of products in development that offer near and long-term growth potential. I believe our technology can change the face of therapy for people with diabetes and I’m excited to be part of what comes next.”

Tandem Diabetes Care Inc. is a global insulin delivery and diabetes technology company based in San Diego, Calif. The company’s human-centered approach to design, development, and support delivers products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology.